<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091220</url>
  </required_header>
  <id_info>
    <org_study_id>CR0001</org_study_id>
    <secondary_id>2009-015216-17</secondary_id>
    <nct_id>NCT01091220</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400 mg on Semen Quality in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on
      the quality of sperm obtained from healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CZP is a PEGylated humanized Fab' fragment with specificity for human tumor necrosis factor
      alpha (TNFα). Evidence suggests that modulation of TNFα signaling may affect male
      spermatogenesis. Therefore, this study will compare semen quality parameters before and after
      a single 400 mg dose of CZP, or matched placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total sperm motility (%)</measure>
    <time_frame>baseline to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm morphology (%)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive motility (%)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-progressive motility (%)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm vitality (%)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semen volume (mL)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm count (millions)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm concentration (millions/mL)</measure>
    <time_frame>Baseline to 99 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sperm Quality</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab pegol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Certolizumab pegol 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously</description>
    <arm_group_label>Certolizumab pegol</arm_group_label>
    <other_name>Cimzia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers with normal baseline semen quality parameters

        Exclusion Criteria:

          -  Previous participation in studies involving TNF inhibitors

          -  Prior treatment with biologic response modifiers within 5 half-lives

          -  History of trauma or surgery to the pelvis/genital area

          -  Tests positive for tuberculosis, HIV, Hepatitis B or C
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <last_update_submitted>September 2, 2011</last_update_submitted>
  <last_update_submitted_qc>September 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>certolizumab pegol</keyword>
  <keyword>Cimzia®</keyword>
  <keyword>healthy male volunteers</keyword>
  <keyword>sperm</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

